DISCOvERIE
Financiado
Development dIagnostic and prevention of gender related Somatic and mental COmo...
Development dIagnostic and prevention of gender related Somatic and mental COmorbitiEs in iRritable bowel syndrome In Europe
Mental (anxiety and depression) and non-mental (fibromyalgia and chronic fatigue syndrome) comorbidities are highly prevalent in irritable bowel syndrome (IBS), with over 60 million Europeans affected, mostly women, by devastating...
Mental (anxiety and depression) and non-mental (fibromyalgia and chronic fatigue syndrome) comorbidities are highly prevalent in irritable bowel syndrome (IBS), with over 60 million Europeans affected, mostly women, by devastating manifestations, impaired treatment and quality of life. Estimated costs are €43 billion/year for IBS, mostly derived from comorbid IBS. Our hypothesis is that comorbid IBS represents a distinct clinical entity, arising from distorted brain-gut communication with a unique, specific, but undefined pathophysiological origin, differing from IBS alone. DISCOvERIE was created to advance the understanding of its causative mechanisms. Identification, validation and comprehension of these mechanisms will help stratify these patients into distinct clinical phenotypes, improving disease management, increasing quality of life and reducing socioeconomic costs. In particular, we will deliver specific comorbid-IBS physiopathological knowledge as clinical guides and protocols for newly created, hospital-based, transversal and multidisciplinary units for implementing personalized management and wellbeing of European citizens and to position Europe as a global leader in comorbid IBS personalised medicine. We will also deliver prognostic and therapeutic biomarkers and patents, technological innovation via e-health tools for personalized assessment of clinical/nutritional/physical activity and disseminate new knowledge widely. Impact will be assessed by recording media presence, scientific publications and by monitoring health-related quality of life of patients and promoting cost-effective care. To this end we have created a user board involving patient associations, clinical specialists, European healthcare experts, large pharma and SMEs representatives. We will also promote the creation of a European Reference Network for comorbid IBS involving healthcare providers across Europe.
ver más
Duración del proyecto: 60 meses
Fecha Inicio: 2019-12-13
Fecha Fin: 2024-12-31
Fecha Fin: 2024-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-12-13
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
6M€
Líder del proyecto
FUNDACIO HOSPITAL UNIVERSITARI VALL HEBRON -...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
33M
Perfil tecnológico
TRL
4-5
33M
278.22K€ |
Participante
520.79K€ |
Participante